2012-10-04 07:54:12 - Recently published research from Global Markets Direct, "Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections. Complicated Intra-Abdominal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468470_complicated_intraabdominal_infections ..


Note*: Certain

sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Complicated Intra-Abdominal Infections.
* A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Complicated Intra-Abdominal Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Complicated Intra-Abdominal Infections Therapeutics - Products under Development by Companies
Companies Involved in Complicated Intra-Abdominal Infections Therapeutics Development
AstraZeneca PLC
Rib-X Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Atox Bio Inc.
Tetraphase Pharmaceuticals Inc.
Complicated Intra-Abdominal Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXA201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-434 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAZ104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXA-201 + Metronidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAZ104 + Metronidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Complicated Intra-Abdominal Infections Therapeutics - Drug Profile Updates
Complicated Intra-Abdominal Infections Therapeutics - Dormant Products
Complicated Intra-Abdominal Infections - Product Development Milestones
Featured News & Press Releases
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections
Jun 16, 2005: FDA Approves Tygacil, First-in-class Antibiotic
May 26, 2005: The US FDA Approves New Indication For Merrem I.V for Complicated Skin and Skin Structure Infections
Jan 28, 2005: FDA Grants Tygacil (Tigecycline) NDA Priority Review Status
Aug 02, 2004: AstraZeneca Submits supplemental New Drug Application to the U.S. Food and Drug Administration for Merrem I.V for a new indication of skin and skin structure infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Complicated Intra-Abdominal Infections, H2 2012
Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468470&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.